Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

ConferencepositiveDecisionDx-MelanomaPositive

AI Analysis

Summary

Late-breaking data from EADV 2026 demonstrates that DecisionDx-Melanoma effectively identifies low-risk patients for sentinel lymph node biopsy decision-making, with low-risk patients showing less than 5% SLN positivity and 99.6% five-year recurrence-free survival when SLNB is avoided.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Data show low-risk DecisionDx-Melanoma patients had SLN positivity below 5% and 99.6% five-year recurrence-free survival when SLNB was avoided

Importance:6/10

Sentiment:

0.75

melanomadiagnosticsentinel lymph node biopsyEADV 2026risk stratificationrecurrence-free survival

Related Companies

$MYRG

Read the original article

Published by PR Newswire Biotech on September 30, 2026 8:30 PM

Read Original